Disease · MONDO_0005306
Comparisons in its trials92
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 92
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Any AIN457 vs Placebo Until Week 16: deaths from any cause | 1 of 517 | 0 of 261 | 778 | NCT04156620 | Trial comparisons |
| Any AIN457 vs Placebo Until Week 16: serious adverse events | 32 of 517 | 3 of 261 | 778 | NCT04156620 | Trial comparisons |
| Any AIN457 150 mg vs Placebo: deaths from any cause | 0 of 453 | 0 of 153 | 606 | NCT02896127 | Trial comparisons |
| Any AIN457 150 mg vs Placebo: serious adverse events | 33 of 453 | 3 of 153 | 606 | NCT02896127 | Trial comparisons |
| Secukinumab vs Placebo: The Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria) | 178 of 305 | 56 of 153 | 458 | NCT02896127 | Trial comparisons |
| Secukinumab vs Placebo: The Proportion of Participants Who Achieve an ASAS40 Response | 138 of 294 | 27 of 146 | 440 | NCT02896127 | Trial comparisons |
| Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria | 114 of 229 | 19 of 115 | 344 | NCT01114880 | Trial comparisons |
| Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the ASAS40 Response Criteria | 102 of 229 | 11 of 115 | 344 | NCT01114880 | Trial comparisons |
| Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants With ASAS Partial Remission | 50 of 229 | 4 of 115 | 344 | NCT01114880 | Trial comparisons |
| Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the ASAS5/6 Response Criteria | 128 of 229 | 14 of 115 | 344 | NCT01114880 | Trial comparisons |
| Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria | 154 of 229 | 35 of 115 | 344 | NCT01114880 | Trial comparisons |
| Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria | 156 of 224 | 71 of 113 | 337 | NCT01114880 | Trial comparisons |
| Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the ASAS5/6 Response Criteria | 150 of 224 | 69 of 113 | 337 | NCT01114880 | Trial comparisons |
| Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the ASAS20 Response Criteria | 180 of 224 | 85 of 113 | 337 | NCT01114880 | Trial comparisons |
| Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants With ASAS Partial Remission | 85 of 224 | 33 of 113 | 337 | NCT01114880 | Trial comparisons |
| Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the ASAS40 Response Criteria | 134 of 224 | 63 of 113 | 337 | NCT01114880 | Trial comparisons |
| Biologic Disease Modifying Anti-Rheumatic Drugs (BDMARD) Naive vs Participants Who Switched From Remicade to CT-P13: Number of Participants With Change in CT-P13 Infusion Dose | 40 of 221 | 8 of 107 | 328 | NCT02605642 | Trial comparisons |
| Biologic Disease Modifying Anti-Rheumatic Drugs (BDMARD) Naive vs Participants Who Switched From Remicade to CT-P13: deaths from any cause | 0 of 221 | 0 of 107 | 328 | NCT02605642 | Trial comparisons |
| Biologic Disease Modifying Anti-Rheumatic Drugs (BDMARD) Naive vs Participants Who Switched From Remicade to CT-P13: serious adverse events | 19 of 221 | 10 of 107 | 328 | NCT02605642 | Trial comparisons |
| CZP 200 mg Q2W (FAS) vs Placebo (FAS): Number of Subjects With Anterior Uveitis (AU) or New AU Flares Through Week 52 | 4 of 159 | 8 of 158 | 317 | NCT02552212 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005306/comparisons